TIGIT overexpression

High levels of TIGIT induced the alteration of CD4+ T cell based immunomodulation and predicted poor prognosis of LUAD patients. Therefore, TIGIT can be potential biomarker for LUAD.

In addition, we designed a single-chain variable fragment derived from the clinically tested monoclonal antibody Vibostolimab targeting TIGIT, and assessed its performance alongside the nanobodies...The excellent affinity, high specificity and rapid on-target uptake in mice bearing TIGIT- overexpressing tumors showed the promising diagnostic potential of nanobodies to noninvasively image high TIGIT expression within the tumor. These findings hold promise for clinical translation to aid patient selection and improve therapy response.

But at MD Anderson, rather than using intensive chemotherapy followed by autologous stem cell therapy, we used Hyper-CVAD rituximab alternating with rituximab plus methotrexate-cytarabine. For elderly patients over 65 years old, we formerly used R-CHOP, but now the international standard is bendamustine-rituximab...In the past 20 years, the FDA has approved many therapies for relapsed mantle cell lymphoma, including the protease inhibitor bortezomib, the cereblon-binding immunomodulator lenalidomide, the first-ever Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, and the second-generation BTK inhibitors acalabrutinib and zanubrutinib...The FDA also approved brexucabtagene autoleucel, a CD19-targeted CAR-T cell therapy and, in January 2023, approved the novel non-covalent reversible BTK inhibitor pirtobrutinib...These included our Window approach, the acalabrutinib-venetoclax-rituximab trial,3 and the acalabrutiniblenalidomide-rituximab (ARL) trial.4 We now have many clinical trials employing rational combinations with targeted agents...We work closely with patients and their families, industry, NIH, and many collaborators within and outside of our institution. We are in the process of saving many lives from mantle cell lymphoma.

Integrative molecular analysis of the tumor microenvironment of GAC identifies an Inflamed class of tumors that complements previously proposed tumor-based molecular clusters (CIN, MSI, EBV, GS). Such findings may provide the rationale for exploring novel immunotherapeutic approaches for biomarker-enriched populations in order to improve GAC patient's survival by means of a paradigm shift in precision immune-oncology.

6 Here, we demonstrate the efficacy and pharmacodynamic (PD) effects of TIGIT ETB in a hTIGIT/PD-1 expressing humanized mouse model...Conclusions These data demonstrate that targeting TIGIT using our Engineered Toxin Body platform promotes tumor regression through elimination of TIGIT/PD-1 co-expressing immune cells within the TME. Our data supports using ETB as a monotherapy to target TIGIT and represents a wholly novel approach for modulating TIGIT within the TME.

Suppressing CD155/TIGIT exerted anti-cancer effects against CRC and our findings provided a potential therapeutic approach to treat CRC.

Present data suggest the combination treatment of TIGIT and HIF-1α as a novel treatment strategy against colorectal and breast cancer, but more researches are required to realize the complete role of TIGIT and HIF-1α inside the TME.

Our results suggest the potential higher vulnerability of IBC to ICIs. Clinical trials.